董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bonnie L. Bassler | 女 | Director | 59 | 11.15万美元 | 未持股 | 2020-12-31 |
| Michael Bonney | 男 | Director | 62 | 13.16万美元 | 未持股 | 2020-12-31 |
| Grady Burnett | 男 | Director | 48 | 11.15万美元 | 未持股 | 2020-12-31 |
| Geoffrey von Maltzahn | 男 | Director | 40 | 11.15万美元 | 未持股 | 2020-12-31 |
| Daniel L. Menichella | 男 | Director, President and Chief Executive Officer | 61 | 394.68万美元 | 未持股 | 2020-12-31 |
| Jean Mixer | 女 | Director | 54 | 11.15万美元 | 未持股 | 2020-12-31 |
| Anne Prener | 女 | Director | 63 | 26.78万美元 | 未持股 | 2020-12-31 |
| Bonnie L Bassler | 女 | Director | 59 | 未披露 | 未持股 | 2020-12-31 |
| Theo Melas Kyriazi | 男 | Director | 61 | 11.15万美元 | 未持股 | 2020-12-31 |
| Anthony G. Quinn | 男 | Director | 59 | 11.15万美元 | 未持股 | 2020-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel L. Menichella | 男 | Director, President and Chief Executive Officer | 61 | 394.68万美元 | 未持股 | 2020-12-31 |
| William Duke, Jr. | 男 | Chief Financial Officer | 48 | 119.99万美元 | 未持股 | 2020-12-31 |
| Johan van Hylckama Vlieg | 男 | Chief Scientific Officer | 52 | 未披露 | 未持股 | 2020-12-31 |
| Jerald Korn | 男 | General Counsel and Chief Administrative Officer | 42 | 未披露 | 未持股 | 2020-12-31 |
董事简历
中英对照 | 中文 | 英文- Bonnie L. Bassler
-
Bonnie L. Bassler博士自2018年12月起担任本公司董事。 Bassler目前在普林斯顿大学担任过多个职位，包括自2013年以来担任分子生物学系主任，自2010年起担任化学系副教授自2008年起担任科学招聘和多样性主任自1994年以来一直担任分子生物学系教授，并于1996年成为普林斯顿环境研究所的副教授。 Bassler博士于2008年7月至2013年6月在普林斯顿大学担任科学与技术总监。自2016年以来2014年斯隆基金会的受托人贝斯勒先后担任了Regeneron制药公司的董事会成员，公司和此前曾担任赛诺菲董事会成员2014年11至9月2016年博士Bassler于2012年1月至2016年12月期间担任美国科学促进会的董事会成员。她于2010年1月至2016年5月期间担任国家科学委员会成员。她获得了B.S。在加州大学戴维斯分校的生物化学和博士学位。约翰霍普金斯大学的生物化学专业。
Bonnie L. Bassler,Chair of the Department of Molecular Biology since 2013 and Squibb Professor in Molecular Biology since 2003 at Princeton University;Howard Hughes Medical Institute Investigator;Former President of the American Society for Microbiology;Former member of the board of the American Association for the Advancement of Science, the National Science Foundation, and the American Academy of Microbiology;MacArthur Foundation Fellowship;Lounsbery Award;Shaw Prize for Life Science and Medicine;Gruber Prize in Genetics;Wolf Prize in Chemistry;Canada Gairdner International Award;Former director of Kaleido Biosciences, Inc. - Bonnie L. Bassler博士自2018年12月起担任本公司董事。 Bassler目前在普林斯顿大学担任过多个职位，包括自2013年以来担任分子生物学系主任，自2010年起担任化学系副教授自2008年起担任科学招聘和多样性主任自1994年以来一直担任分子生物学系教授，并于1996年成为普林斯顿环境研究所的副教授。 Bassler博士于2008年7月至2013年6月在普林斯顿大学担任科学与技术总监。自2016年以来2014年斯隆基金会的受托人贝斯勒先后担任了Regeneron制药公司的董事会成员，公司和此前曾担任赛诺菲董事会成员2014年11至9月2016年博士Bassler于2012年1月至2016年12月期间担任美国科学促进会的董事会成员。她于2010年1月至2016年5月期间担任国家科学委员会成员。她获得了B.S。在加州大学戴维斯分校的生物化学和博士学位。约翰霍普金斯大学的生物化学专业。
- Bonnie L. Bassler,Chair of the Department of Molecular Biology since 2013 and Squibb Professor in Molecular Biology since 2003 at Princeton University;Howard Hughes Medical Institute Investigator;Former President of the American Society for Microbiology;Former member of the board of the American Association for the Advancement of Science, the National Science Foundation, and the American Academy of Microbiology;MacArthur Foundation Fellowship;Lounsbery Award;Shaw Prize for Life Science and Medicine;Gruber Prize in Genetics;Wolf Prize in Chemistry;Canada Gairdner International Award;Former director of Kaleido Biosciences, Inc.
- Michael Bonney
-
Michael Bonney自2017年6月起担任董事会执行主席。此前，Bonney先生于2017年6月至2018年8月担任我们的首席执行官。Bonney先生自2018年6月起还担任生物技术公司MagentaTherapeutics，Inc.的董事会主席，他曾于2016年11月至2018年6月担任执行主席。此前，他曾担任Third Rock Ventures公司（风险投资公司）的合伙人（2016年1月至2016年7月）。在加入Third Rock Ventures，LLC之前，Bonney先生曾于2003年至2015年担任生物制药公司CubistPharmaceuticals，Inc.的首席执行官兼董事，该公司被默克收购。除了担任Magenta董事会主席外，Bonney先生还担任AlnylamPharmaceuticals，Inc.董事会和贝茨学院董事会主席。他还自2015年起担任新基医药公司SareptaTherapeutics，Inc.的董事会成员，自2017年起担任Syros Therapeutics的董事会成员。Bonney先生曾于2016年至2017年担任Global Blood Therapeutics董事会成员，并于2005年至2015年担任NPSPharmaceuticals，Inc.董事会成员。他在贝茨学院（Bates College）获得经济学学士学位。
Michael Bonney has served as the Chair of the Board of Directors since October 2020. Mr. Bonney has also served as Managing Director of Sasanoa Advisory Group Enterprises, LLC, a CEO advisory firm, since June 2019. Previously, Mr. Bonney served as our Chief Executive Officer and Chair of the Board of Directors from June 2017 until August 2018 and as Executive Chair of the Board of Directors from August 2018 until October 2020. Mr. Bonney has also served as Chairman of the board of directors of Magenta Therapeutics, Inc., a biotechnology company, since June 2018 and he previously served as Executive Chairman from November 2016 until June 2018. Prior to that, he served as Partner at Third Rock Ventures, LLC, a venture capital firm, from January 2016 to July 2016. Before joining Third Rock Ventures, LLC, Mr. Bonney served as CEO and Director at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 until 2015 when it was acquired by Merck. In addition to his role as Chairman of the board of Magenta, Mr. Bonney chairs the board of directors of Alnylam Pharmaceuticals, Inc. Mr. Bonney serves as a board member of Bristol-Myers Squibb, since the acquisition of Celgene in November 2019. Mr. Bonney previously served on the boards of Sarepta Therapeutics, Inc. from December 2017 to March 2020 Syros Therapeutics from June 2018 to March 2020 since June 2018. Global Blood Therapeutics from 2016 to 2017 Revolution Medicines from 2016 to 2017 and NPS Pharmaceuticals, Inc. from 2005 to 2015. He received a B.A. in economics from Bates College. - Michael Bonney自2017年6月起担任董事会执行主席。此前，Bonney先生于2017年6月至2018年8月担任我们的首席执行官。Bonney先生自2018年6月起还担任生物技术公司MagentaTherapeutics，Inc.的董事会主席，他曾于2016年11月至2018年6月担任执行主席。此前，他曾担任Third Rock Ventures公司（风险投资公司）的合伙人（2016年1月至2016年7月）。在加入Third Rock Ventures，LLC之前，Bonney先生曾于2003年至2015年担任生物制药公司CubistPharmaceuticals，Inc.的首席执行官兼董事，该公司被默克收购。除了担任Magenta董事会主席外，Bonney先生还担任AlnylamPharmaceuticals，Inc.董事会和贝茨学院董事会主席。他还自2015年起担任新基医药公司SareptaTherapeutics，Inc.的董事会成员，自2017年起担任Syros Therapeutics的董事会成员。Bonney先生曾于2016年至2017年担任Global Blood Therapeutics董事会成员，并于2005年至2015年担任NPSPharmaceuticals，Inc.董事会成员。他在贝茨学院（Bates College）获得经济学学士学位。
- Michael Bonney has served as the Chair of the Board of Directors since October 2020. Mr. Bonney has also served as Managing Director of Sasanoa Advisory Group Enterprises, LLC, a CEO advisory firm, since June 2019. Previously, Mr. Bonney served as our Chief Executive Officer and Chair of the Board of Directors from June 2017 until August 2018 and as Executive Chair of the Board of Directors from August 2018 until October 2020. Mr. Bonney has also served as Chairman of the board of directors of Magenta Therapeutics, Inc., a biotechnology company, since June 2018 and he previously served as Executive Chairman from November 2016 until June 2018. Prior to that, he served as Partner at Third Rock Ventures, LLC, a venture capital firm, from January 2016 to July 2016. Before joining Third Rock Ventures, LLC, Mr. Bonney served as CEO and Director at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 until 2015 when it was acquired by Merck. In addition to his role as Chairman of the board of Magenta, Mr. Bonney chairs the board of directors of Alnylam Pharmaceuticals, Inc. Mr. Bonney serves as a board member of Bristol-Myers Squibb, since the acquisition of Celgene in November 2019. Mr. Bonney previously served on the boards of Sarepta Therapeutics, Inc. from December 2017 to March 2020 Syros Therapeutics from June 2018 to March 2020 since June 2018. Global Blood Therapeutics from 2016 to 2017 Revolution Medicines from 2016 to 2017 and NPS Pharmaceuticals, Inc. from 2005 to 2015. He received a B.A. in economics from Bates College.
- Grady Burnett
-
Grady Burnett自2018年9月起担任公司董事。Burnett先生目前担任Bow Capital（一家早期风险投资公司）的普通合伙人，自2016年7月共同创立公司以来，他一直担任该职位。此前，他曾担任HackerRank公司（技术公司）的总裁兼首席运营官（2015年9月至2016年7月）。在此之前，2013年9月至2014年10月，Burnett先生担任Flurry，Inc.的首席运营官，该公司是一家移动分析，货币化和广告公司。Burnett先生还从2009年到2013年担任Facebook，Inc.全球销售和运营的Vice President，之前也是Google LLC AdWords团队的北美销售和运营总监。Burnett先生是East Palo Alto Tennis&Tutching，Menlo School和Kenshoo，Ltd.的董事会成员。他拥有哈佛商学院（Harvard Business School）的工商管理硕士学位，是密歇根大学（University of Michigan）的毕业生。
Grady Burnett has served as a Director of our company since September 2018. Mr. Burnett currently serves as the General Partner at Bow Capital, an early stage venture capital firm, a position he has held since co-founding the company in July 2016. Previously, he served as the President and Chief Operating Officer of HackerRank, a technology company, from September 2015 until July 2016. Before that, from September 2013 until October 2014 Mr. Burnett served as the Chief Operating Officer of Flurry, Inc., a mobile analytics, monetization and advertising company. Mr. Burnett has also served as Vice President of Global Sales and Operations at Facebook, Inc. from 2009 to 2013 and was also previously the Director of North American Sales and Operations for Google LLC’s AdWords team. Mr. Burnett is a member of the board of directors of East Palo Alto Tennis & Tutoring, Menlo School and Kenshoo, Ltd. He has an M.B.A. from the Harvard Business School and a bachelor’s degree from the University of Michigan. - Grady Burnett自2018年9月起担任公司董事。Burnett先生目前担任Bow Capital（一家早期风险投资公司）的普通合伙人，自2016年7月共同创立公司以来，他一直担任该职位。此前，他曾担任HackerRank公司（技术公司）的总裁兼首席运营官（2015年9月至2016年7月）。在此之前，2013年9月至2014年10月，Burnett先生担任Flurry，Inc.的首席运营官，该公司是一家移动分析，货币化和广告公司。Burnett先生还从2009年到2013年担任Facebook，Inc.全球销售和运营的Vice President，之前也是Google LLC AdWords团队的北美销售和运营总监。Burnett先生是East Palo Alto Tennis&Tutching，Menlo School和Kenshoo，Ltd.的董事会成员。他拥有哈佛商学院（Harvard Business School）的工商管理硕士学位，是密歇根大学（University of Michigan）的毕业生。
- Grady Burnett has served as a Director of our company since September 2018. Mr. Burnett currently serves as the General Partner at Bow Capital, an early stage venture capital firm, a position he has held since co-founding the company in July 2016. Previously, he served as the President and Chief Operating Officer of HackerRank, a technology company, from September 2015 until July 2016. Before that, from September 2013 until October 2014 Mr. Burnett served as the Chief Operating Officer of Flurry, Inc., a mobile analytics, monetization and advertising company. Mr. Burnett has also served as Vice President of Global Sales and Operations at Facebook, Inc. from 2009 to 2013 and was also previously the Director of North American Sales and Operations for Google LLC’s AdWords team. Mr. Burnett is a member of the board of directors of East Palo Alto Tennis & Tutoring, Menlo School and Kenshoo, Ltd. He has an M.B.A. from the Harvard Business School and a bachelor’s degree from the University of Michigan.
- Geoffrey von Maltzahn
-
Geoffrey von Maltzahn是Sana Biotechnology的联合创始人，自2019年2月起担任董事会成员。Von Maltzahn博士是Flagship先锋公司的普通合伙人，专注于创新和公司创立，自2009年11月以来一直在Flagship公司任职。Von Maltzahn博士带领旗舰实验室的创新团队创立了Cobalt Biomedicine，并担任其首席执行官和董事会成员，直到2019年2月该公司与Sana Biotechnology合并。Von Maltzahn博士目前担任Tessera Therapeutics的首席执行官兼董事，以及Generate Biomedicine的联席首席执行官。此前，Von Maltzahn博士于2015年至2017年担任Kaleido&8217；s首席执行官，并在公司董事会任职。Von Maltzahn博士还担任Indigo Agriculture，Inc.的首席创新官和董事，该公司是他于2013年共同创立的农业生物技术公司，是Flagship Pioneural’；s Flagship Labs创新铸造厂的一部分。Von Maltzahn博士在2010年是赛里斯治疗公司的联合创始人，他在SERES担任首席技术官直到2012年。Von Maltzahn博士在麻省理工学院（MIT）获得生物医学工程与医学物理学博士学位，在加州大学圣地亚哥分校（University of California，San Diego）获得生物工程硕士学位，在麻省理工学院（MIT）获得化学工程学士学位。
Geoffrey von Maltzahn has served as a Director for our company since August 2015 and also acts as an advisor on new innovation opportunities for our product platform, technology and approach to targeting the microbiome organ. He is a General Partner at Flagship Pioneering an innovation enterprise that conceives, creates, resources and grows first-in-category life sciences companies, focused on company origination and has been with Flagship since 2009. Dr. von Maltzahn was founder of our company and served as our Chief Executive Officer from January 2015 to June 2017 and as Chief Innovation Officer from June 2017 to September 2018. Dr. von Maltzahn also serves as the Chief Innovation Officer of Indigo Agriculture, Inc., an agriculture biotechnology company he co-founded in 2013 as part of Flagship Pioneering’s Flagship Labs innovation foundry. Dr. von Maltzahn was also a member of the Flagship Pioneering founding team for Seres Therapeutics, Inc. in 2010 and he subsequently served as Chief Technology Officer at Seres in 2012. Prior to working on Seres, Dr. von Maltzahn worked on the Flagship Pioneering founding team for Axcella Health, Inc., a biotechnology company, in 2009 and he served as Vice President of Discovery at Axcella from 2009 until 2013. Dr. von Maltzahn has been a member of the Board of Directors of Sana Biotechnology since 2018. He was awarded a Ph.D. in biomedical engineering and medical physics from MIT, a M.S. in bioengineering from the University of California, San Diego, and an S.B. in chemical engineering from MIT. - Geoffrey von Maltzahn是Sana Biotechnology的联合创始人，自2019年2月起担任董事会成员。Von Maltzahn博士是Flagship先锋公司的普通合伙人，专注于创新和公司创立，自2009年11月以来一直在Flagship公司任职。Von Maltzahn博士带领旗舰实验室的创新团队创立了Cobalt Biomedicine，并担任其首席执行官和董事会成员，直到2019年2月该公司与Sana Biotechnology合并。Von Maltzahn博士目前担任Tessera Therapeutics的首席执行官兼董事，以及Generate Biomedicine的联席首席执行官。此前，Von Maltzahn博士于2015年至2017年担任Kaleido&8217；s首席执行官，并在公司董事会任职。Von Maltzahn博士还担任Indigo Agriculture，Inc.的首席创新官和董事，该公司是他于2013年共同创立的农业生物技术公司，是Flagship Pioneural’；s Flagship Labs创新铸造厂的一部分。Von Maltzahn博士在2010年是赛里斯治疗公司的联合创始人，他在SERES担任首席技术官直到2012年。Von Maltzahn博士在麻省理工学院（MIT）获得生物医学工程与医学物理学博士学位，在加州大学圣地亚哥分校（University of California，San Diego）获得生物工程硕士学位，在麻省理工学院（MIT）获得化学工程学士学位。
- Geoffrey von Maltzahn has served as a Director for our company since August 2015 and also acts as an advisor on new innovation opportunities for our product platform, technology and approach to targeting the microbiome organ. He is a General Partner at Flagship Pioneering an innovation enterprise that conceives, creates, resources and grows first-in-category life sciences companies, focused on company origination and has been with Flagship since 2009. Dr. von Maltzahn was founder of our company and served as our Chief Executive Officer from January 2015 to June 2017 and as Chief Innovation Officer from June 2017 to September 2018. Dr. von Maltzahn also serves as the Chief Innovation Officer of Indigo Agriculture, Inc., an agriculture biotechnology company he co-founded in 2013 as part of Flagship Pioneering’s Flagship Labs innovation foundry. Dr. von Maltzahn was also a member of the Flagship Pioneering founding team for Seres Therapeutics, Inc. in 2010 and he subsequently served as Chief Technology Officer at Seres in 2012. Prior to working on Seres, Dr. von Maltzahn worked on the Flagship Pioneering founding team for Axcella Health, Inc., a biotechnology company, in 2009 and he served as Vice President of Discovery at Axcella from 2009 until 2013. Dr. von Maltzahn has been a member of the Board of Directors of Sana Biotechnology since 2018. He was awarded a Ph.D. in biomedical engineering and medical physics from MIT, a M.S. in bioengineering from the University of California, San Diego, and an S.B. in chemical engineering from MIT.
- Daniel L. Menichella
-
Daniel L.Menichella自2020年10月起担任我们的首席执行官兼总裁兼董事。在成为首席执行官之前，他于2017年1月担任CureVac Inc.’；S美国子公司的首席执行官，然后于2018年6月接任该国际公司的首席执行官。在此之前，Menichella先生曾担任多家公司的首席商务官，包括Bamboo Therapeutics Inc.（2015年至2016年），2013年至2015年担任Applied Genetic Technologies Corporation AGTC，以及Zyngenia，Inc.（2011年至2013年）。Menichella先生还从2007年到2011年领导Talecris Biopharmicals的业务开发和公司战略职能部门，从2002年到2007年领导Merck KGaA的业务开发和公司战略部门。他在哈佛大学获得文学士学位，在北卡罗来纳大学教堂山分校获得工商管理硕士学位。
Daniel L. Menichella has served as our Chief Executive Officer and President and as a Director since October 2020. Prior to becoming Chief Executive Officer, he served as the chief executive officer for CureVac Inc.’s U.S. subsidiary in January 2017 before taking over as CEO of the international company in June 2018. Prior to that, Mr. Menichella was Chief Business Officer at several companies, including Bamboo Therapeutics Inc. from 2015-2016 Applied Genetic Technologies Corporation AGTC from 2013-2015 and Zyngenia, Inc. from 2011-2013. Mr. Menichella also led Business Development and Corporate Strategy functions at Talecris Biopharmaceuticals from 2007-2011 and at Merck KGaA from 2002-2007. He earned his Bachelor of Arts from Harvard University and his Master of Business Administration from the University of North Carolina at Chapel Hill. - Daniel L.Menichella自2020年10月起担任我们的首席执行官兼总裁兼董事。在成为首席执行官之前，他于2017年1月担任CureVac Inc.’；S美国子公司的首席执行官，然后于2018年6月接任该国际公司的首席执行官。在此之前，Menichella先生曾担任多家公司的首席商务官，包括Bamboo Therapeutics Inc.（2015年至2016年），2013年至2015年担任Applied Genetic Technologies Corporation AGTC，以及Zyngenia，Inc.（2011年至2013年）。Menichella先生还从2007年到2011年领导Talecris Biopharmicals的业务开发和公司战略职能部门，从2002年到2007年领导Merck KGaA的业务开发和公司战略部门。他在哈佛大学获得文学士学位，在北卡罗来纳大学教堂山分校获得工商管理硕士学位。
- Daniel L. Menichella has served as our Chief Executive Officer and President and as a Director since October 2020. Prior to becoming Chief Executive Officer, he served as the chief executive officer for CureVac Inc.’s U.S. subsidiary in January 2017 before taking over as CEO of the international company in June 2018. Prior to that, Mr. Menichella was Chief Business Officer at several companies, including Bamboo Therapeutics Inc. from 2015-2016 Applied Genetic Technologies Corporation AGTC from 2013-2015 and Zyngenia, Inc. from 2011-2013. Mr. Menichella also led Business Development and Corporate Strategy functions at Talecris Biopharmaceuticals from 2007-2011 and at Merck KGaA from 2002-2007. He earned his Bachelor of Arts from Harvard University and his Master of Business Administration from the University of North Carolina at Chapel Hill.
- Jean Mixer
-
Jean Mixer自2019年10月起担任公司董事。Mixer女士拥有超过25年的医疗保健经验，并在上市公司董事会任职15年。她是MixerConsulting的创始人兼首席执行官。2014年至2020年，Mixer女士担任波士顿儿童医院（Boston Children’；s Hospital，哈佛附属医院）的首席数字转型官兼副总裁战略。在此之前，她是The Boston Consulting Group的合伙人，这是一家全球战略咨询公司，她在该公司工作了十多年。Mixer女士在整个医疗保健价值链中拥有丰富的经验，包括在领先的生物制药、制药/PBMS、医疗设备和数字健康公司的执行管理层和董事会工作，以及供应商和付款人。她的职业生涯始于纽约的J.P.Morgan。2012年至2019年，Mixer女士曾在NxStage Medical, Inc.的董事会任职，当时该公司以20亿美元的价格被收购。她获得了西北大学凯洛格管理学院的管理学硕士学位。
Jean Mixer has served as a Director of our company since October 2019. Ms. Mixer has more than 25 years of experience in healthcare and 15 years serving on public company boards. She is founder and CEO of mixerconsulting. Ms. Mixer was Chief Digital Transformation Officer and Vice President Strategy, at Boston Children’s Hospital, a Harvard affiliate from 2014 to 2020. Prior to that, she was a partner at the Boston Consulting Group, a global strategy consulting firm where she worked for over a decade. Ms. Mixer has broad experience across the healthcare value chain, including working with executive management and Boards of leading biopharmaceutical, pharmacy/PBMs, medical device and digital health companies, and as well as providers and payers. She began her career at J.P. Morgan in New York. Ms. Mixer previously served on the Board of Directors of NxStage Medical, Inc. from 2012 to 2019 when it was acquired for $2 billion. She received a master’s degree in Management from the Kellogg School of Management, Northwestern University. - Jean Mixer自2019年10月起担任公司董事。Mixer女士拥有超过25年的医疗保健经验，并在上市公司董事会任职15年。她是MixerConsulting的创始人兼首席执行官。2014年至2020年，Mixer女士担任波士顿儿童医院（Boston Children’；s Hospital，哈佛附属医院）的首席数字转型官兼副总裁战略。在此之前，她是The Boston Consulting Group的合伙人，这是一家全球战略咨询公司，她在该公司工作了十多年。Mixer女士在整个医疗保健价值链中拥有丰富的经验，包括在领先的生物制药、制药/PBMS、医疗设备和数字健康公司的执行管理层和董事会工作，以及供应商和付款人。她的职业生涯始于纽约的J.P.Morgan。2012年至2019年，Mixer女士曾在NxStage Medical, Inc.的董事会任职，当时该公司以20亿美元的价格被收购。她获得了西北大学凯洛格管理学院的管理学硕士学位。
- Jean Mixer has served as a Director of our company since October 2019. Ms. Mixer has more than 25 years of experience in healthcare and 15 years serving on public company boards. She is founder and CEO of mixerconsulting. Ms. Mixer was Chief Digital Transformation Officer and Vice President Strategy, at Boston Children’s Hospital, a Harvard affiliate from 2014 to 2020. Prior to that, she was a partner at the Boston Consulting Group, a global strategy consulting firm where she worked for over a decade. Ms. Mixer has broad experience across the healthcare value chain, including working with executive management and Boards of leading biopharmaceutical, pharmacy/PBMs, medical device and digital health companies, and as well as providers and payers. She began her career at J.P. Morgan in New York. Ms. Mixer previously served on the Board of Directors of NxStage Medical, Inc. from 2012 to 2019 when it was acquired for $2 billion. She received a master’s degree in Management from the Kellogg School of Management, Northwestern University.
- Anne Prener
-
Anne Prener自2020年4月起担任公司董事。Prener博士目前是SV Health Investors的风险合伙人，自2020年9月起担任该职位，并自2020年7月起担任Imbria Pharmaceuticals的总裁兼首席执行官。Prener博士在生命科学公司拥有超过25年的领导经验，并于2017年7月至2019年6月担任Freeline Ltd.的首席执行官兼董事。Prener博士领导了多个治疗领域的公司和团队，包括关注罕见病。在加入Freeline之前，她于2016年8月至2020年7月担任专注于眼疾的基因治疗公司Gyroscope Therapeutics Ltd.的首席执行官。在此之前，从2014年10月到2016年7月，Prener博士担任Baxalta的血液学和副总裁临床研究血液学全球治疗领域负责人。职业生涯早期，她曾担任Novo Nordisk公司的多种职务，并不断被提拔，最近担任血友病研发投资组合的高级副总裁，在那里她曾帮助建立晚期和商业血友病产品的投资组合。Prener博士自2020年1月起担任Renovacor，Inc.的董事会成员，自2019年12月起担任Rubius Therapeutics, Inc.，自2021年1月起担任Galecto，Inc.的董事会成员。Prener博士曾于2017年7月至2020年3月担任Gyroscope Therapeutics Ltd.的董事，并于2020年3月至2020年6月担任Cellinta Ltd.的董事。她拥有哥本哈根大学的流行病学博士学位和医学博士学位。
Anne Prener has served as a Director of our company since April 2020. Dr. Prener is currently a Venture Partner at SV Health Investors, a role she has held since September of 2020 and President and CEO of Imbria Pharmaceuticals, where she has served since July 2020. Dr. Prener has more than 25 years of leadership experience within life sciences companies and served as CEO and Director of Freeline Ltd. from July of 2017 to June of 2019. Dr. Prener has led companies and teams across several therapeutic areas, including a focus on rare diseases. Prior to joining Freeline, she served as CEO of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases, from August 2016 to July 2020. Before that, Dr. Prener was Global Therapeutic Area Head of Hematology and Vice President, Clinical Research Hematology at Baxalta from October 2014 to July 2016. Earlier in her career, Dr. Prener held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D Portfolio, where she was instrumental in building a portfolio of late stage and commercial hemophilia products. Dr. Prener serves on the Boards of Directors of Renovacor, Inc. since January of 2020 Rubius Therapeutics, Inc. since December 2019 and Galecto, Inc. since January of 2021. Dr. Prener previously served as a director of Gyroscope Therapeutics Ltd. from July 2017 to March 2020 and of Cellinta Ltd. from March 2020 to June 2020. She holds a Ph.D. in epidemiology and an M.D., both from the University of Copenhagen. - Anne Prener自2020年4月起担任公司董事。Prener博士目前是SV Health Investors的风险合伙人，自2020年9月起担任该职位，并自2020年7月起担任Imbria Pharmaceuticals的总裁兼首席执行官。Prener博士在生命科学公司拥有超过25年的领导经验，并于2017年7月至2019年6月担任Freeline Ltd.的首席执行官兼董事。Prener博士领导了多个治疗领域的公司和团队，包括关注罕见病。在加入Freeline之前，她于2016年8月至2020年7月担任专注于眼疾的基因治疗公司Gyroscope Therapeutics Ltd.的首席执行官。在此之前，从2014年10月到2016年7月，Prener博士担任Baxalta的血液学和副总裁临床研究血液学全球治疗领域负责人。职业生涯早期，她曾担任Novo Nordisk公司的多种职务，并不断被提拔，最近担任血友病研发投资组合的高级副总裁，在那里她曾帮助建立晚期和商业血友病产品的投资组合。Prener博士自2020年1月起担任Renovacor，Inc.的董事会成员，自2019年12月起担任Rubius Therapeutics, Inc.，自2021年1月起担任Galecto，Inc.的董事会成员。Prener博士曾于2017年7月至2020年3月担任Gyroscope Therapeutics Ltd.的董事，并于2020年3月至2020年6月担任Cellinta Ltd.的董事。她拥有哥本哈根大学的流行病学博士学位和医学博士学位。
- Anne Prener has served as a Director of our company since April 2020. Dr. Prener is currently a Venture Partner at SV Health Investors, a role she has held since September of 2020 and President and CEO of Imbria Pharmaceuticals, where she has served since July 2020. Dr. Prener has more than 25 years of leadership experience within life sciences companies and served as CEO and Director of Freeline Ltd. from July of 2017 to June of 2019. Dr. Prener has led companies and teams across several therapeutic areas, including a focus on rare diseases. Prior to joining Freeline, she served as CEO of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases, from August 2016 to July 2020. Before that, Dr. Prener was Global Therapeutic Area Head of Hematology and Vice President, Clinical Research Hematology at Baxalta from October 2014 to July 2016. Earlier in her career, Dr. Prener held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D Portfolio, where she was instrumental in building a portfolio of late stage and commercial hemophilia products. Dr. Prener serves on the Boards of Directors of Renovacor, Inc. since January of 2020 Rubius Therapeutics, Inc. since December 2019 and Galecto, Inc. since January of 2021. Dr. Prener previously served as a director of Gyroscope Therapeutics Ltd. from July 2017 to March 2020 and of Cellinta Ltd. from March 2020 to June 2020. She holds a Ph.D. in epidemiology and an M.D., both from the University of Copenhagen.
- Bonnie L Bassler
-
暂无中文简介
Bonnie L Bassler has served as a Director of our company since December 2018. Dr. Bassler currently serves in several roles at Princeton University, including, Chair of the Department of Molecular Biology since 2013 associated faculty member of the Department of Chemistry since 2010 Director for Recruiting and Diversity in the Sciences since 2008 investigator at the Howard Hughes Medical Institute since 2005 professor in the Department of Molecular Biology since 1994 and associate faculty member of the Princeton Environmental Institute since 1996. Previously, Dr. Bassler served as the Director of the Council on Science and Technology at Princeton University from July 2008 to June 2013. Dr. Bassler has served as a board member of Regeneron Pharmaceuticals, Inc. since 2016 a board member of Cidara Therapeutics since 2021 as a Trustee of the Alfred P. Sloan Foundation since 2014 and previously served as a board member of Sanofi from November 2014 to September 2016. Dr. Bassler served as a board member of the American Association for the Advancement of Science from January 2012 to December 2016. She was a member of the National Science Board from January 2010 until May 2016. She received a B.S. in biochemistry from the University of California-Davis and a Ph.D. in biochemistry from John Hopkins University. -
暂无中文简介
- Bonnie L Bassler has served as a Director of our company since December 2018. Dr. Bassler currently serves in several roles at Princeton University, including, Chair of the Department of Molecular Biology since 2013 associated faculty member of the Department of Chemistry since 2010 Director for Recruiting and Diversity in the Sciences since 2008 investigator at the Howard Hughes Medical Institute since 2005 professor in the Department of Molecular Biology since 1994 and associate faculty member of the Princeton Environmental Institute since 1996. Previously, Dr. Bassler served as the Director of the Council on Science and Technology at Princeton University from July 2008 to June 2013. Dr. Bassler has served as a board member of Regeneron Pharmaceuticals, Inc. since 2016 a board member of Cidara Therapeutics since 2021 as a Trustee of the Alfred P. Sloan Foundation since 2014 and previously served as a board member of Sanofi from November 2014 to September 2016. Dr. Bassler served as a board member of the American Association for the Advancement of Science from January 2012 to December 2016. She was a member of the National Science Board from January 2010 until May 2016. She received a B.S. in biochemistry from the University of California-Davis and a Ph.D. in biochemistry from John Hopkins University.
- Theo Melas Kyriazi
-
Theo Melas Kyriazi ，他一直任职公司的董事会（2010年9月以来）。他一直担任Levitronix Technologies公司（磁悬浮轴承电动机技术领域的世界领导者）的首席财务官（2011年以来），也曾担任Levitronix公司（Levitronix Technologies公司的附属机构）的首席财务官（2006年以来）。他曾担任Thermo Electron Corporation的首席财务官（从1999年1月到2004年10月）。他曾担任Thermo Electron Corporation的主管公司策略的副总裁（1998年）、Thermo Spectra Corporation（Thermo Electron公司的上市控股子公司）的首席执行官（从1994年到1998年），也曾担任Thermo Electron Corporation及其上市子公司的财务主管（从1988年到1994年）。他目前担任Moderna Therapeutics公司和GeNO公司的董事。他是VPI公司、Helicos BioSciences Corporation、 Cyberkinetics Neurotechnology Systems公司、Glenrose Instruments公司的前任董事。
Theo Melas Kyriazi has served as a Director for our company since July 2019. Mr. Melas-Kyriazi has served as Chief Financial Officer of Levitronix Technologies Inc. and its predecessor companies since 2006. Levitronix Technologies Inc. manufactures and sells magnetically-levitated pumps primarily to microelectronics and life sciences customers. Mr. Melas-Kyriazi also serves as an Executive Partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and grows first-in-category life sciences companies, which he joined in April 2019. Mr. Melas-Kyriazi has served as a board member of Evelo Biosciences, Inc. since 2017 and of Codiak Biosciences, Inc. since 2019. He also served as a director at Valeant Pharmaceuticals International, Inc from 2003 to 2016. From 1986 to 2004 Mr. Melas-Kyriazi served in a variety of management roles at Thermo Fisher Scientific. Mr. Melas-Kyriazi received his M.B.A. from Harvard Business School. - Theo Melas Kyriazi ，他一直任职公司的董事会（2010年9月以来）。他一直担任Levitronix Technologies公司（磁悬浮轴承电动机技术领域的世界领导者）的首席财务官（2011年以来），也曾担任Levitronix公司（Levitronix Technologies公司的附属机构）的首席财务官（2006年以来）。他曾担任Thermo Electron Corporation的首席财务官（从1999年1月到2004年10月）。他曾担任Thermo Electron Corporation的主管公司策略的副总裁（1998年）、Thermo Spectra Corporation（Thermo Electron公司的上市控股子公司）的首席执行官（从1994年到1998年），也曾担任Thermo Electron Corporation及其上市子公司的财务主管（从1988年到1994年）。他目前担任Moderna Therapeutics公司和GeNO公司的董事。他是VPI公司、Helicos BioSciences Corporation、 Cyberkinetics Neurotechnology Systems公司、Glenrose Instruments公司的前任董事。
- Theo Melas Kyriazi has served as a Director for our company since July 2019. Mr. Melas-Kyriazi has served as Chief Financial Officer of Levitronix Technologies Inc. and its predecessor companies since 2006. Levitronix Technologies Inc. manufactures and sells magnetically-levitated pumps primarily to microelectronics and life sciences customers. Mr. Melas-Kyriazi also serves as an Executive Partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and grows first-in-category life sciences companies, which he joined in April 2019. Mr. Melas-Kyriazi has served as a board member of Evelo Biosciences, Inc. since 2017 and of Codiak Biosciences, Inc. since 2019. He also served as a director at Valeant Pharmaceuticals International, Inc from 2003 to 2016. From 1986 to 2004 Mr. Melas-Kyriazi served in a variety of management roles at Thermo Fisher Scientific. Mr. Melas-Kyriazi received his M.B.A. from Harvard Business School.
- Anthony G. Quinn
-
Anthony G. Quinn，担任公司执行副总裁兼首席医疗官，是研究和开发负责人。Quinn博士自从公司合并以来担任公司的执行官，在那之前，2009年8月以来在Private Synageva担任相同的职位。在加入公司之前，他是罗氏副总裁和炎症临床研究和探索研究全球负责人。在罗氏的时候，Quinn博士管理风湿病学和呼吸道探索开发，以及MabThera，Rituxan， Actemra 和Ocrelizumab后期临床和注册阶段的生物标志物和转化医学的项目管理。Quinn博士2005年加入罗氏，建立转化医学，探索大范围医疗领域开发包括中枢神经系统、病毒学和炎症。在加入罗氏之前，他是英国AstraZeneca, Charnwood的试验医疗董事，在那之前，他是英国伦敦Barts & The London School of Medicine的皮肤医学教授。他撰写或者联合撰写了50多篇同行审阅的期刊文章、书刊篇章、评论和述评，主要关于刺猬信号和非黑瘤皮肤癌分子生物学。他拥有医疗科学第一荣誉学士学位，以及英国邓迪大学医学士，外科学士和医学博士的学位。Quinn博士在泰恩河畔纽卡斯尔大学完成内科、皮肤科和分子生物学训练，也在那里获得了博士学位。他完成了旧金山加利福尼亚大学博士后经历，是伦敦皇家内科医学院的研究员。
Anthony G. Quinn has served as a Director for our company since February 2016. Currently Dr. Quinn is President and Chief Executive Officer of Aeglea BioTherapeutics, Inc., a biotechnology company where he has served on the Board of Directors since April 2015 as CEO since July 2018 and as interim CEO from July 2017 to July 2018. Prior to that, from October 2015 to July 2017 he worked as a private consultant for IDBioPharm Consulting LLC, a consulting firm. From August 2009 to June 2015 Dr. Quinn served as Head of Research & Development and Chief Medical Officer for Synageva BioPharma Corp., a publicly traded biopharmaceutical company that was acquired by Alexion Pharmaceuticals, Inc. in June 2015. Following the acquisition, Dr. Quinn worked for Alexion Pharmaceuticals, Inc., a pharmaceutical company, from June 2015 to September 2015. Dr. Quinn received his BMSc. in general pathology and his MB ChB M.D. from the University of Dundee, U.K. and his Ph.D. in cancer research from the University of Newcastle in Tyne, U.K. He completed a postdoctoral fellowship at University of California, San Francisco before being appointed Professor of Dermatology at Barts & The London School of Medicine, U.K. He is a fellow of the Royal College of Physicians London. He has also served as a member of the board of directors for Generation Bio since December 2017. - Anthony G. Quinn，担任公司执行副总裁兼首席医疗官，是研究和开发负责人。Quinn博士自从公司合并以来担任公司的执行官，在那之前，2009年8月以来在Private Synageva担任相同的职位。在加入公司之前，他是罗氏副总裁和炎症临床研究和探索研究全球负责人。在罗氏的时候，Quinn博士管理风湿病学和呼吸道探索开发，以及MabThera，Rituxan， Actemra 和Ocrelizumab后期临床和注册阶段的生物标志物和转化医学的项目管理。Quinn博士2005年加入罗氏，建立转化医学，探索大范围医疗领域开发包括中枢神经系统、病毒学和炎症。在加入罗氏之前，他是英国AstraZeneca, Charnwood的试验医疗董事，在那之前，他是英国伦敦Barts & The London School of Medicine的皮肤医学教授。他撰写或者联合撰写了50多篇同行审阅的期刊文章、书刊篇章、评论和述评，主要关于刺猬信号和非黑瘤皮肤癌分子生物学。他拥有医疗科学第一荣誉学士学位，以及英国邓迪大学医学士，外科学士和医学博士的学位。Quinn博士在泰恩河畔纽卡斯尔大学完成内科、皮肤科和分子生物学训练，也在那里获得了博士学位。他完成了旧金山加利福尼亚大学博士后经历，是伦敦皇家内科医学院的研究员。
- Anthony G. Quinn has served as a Director for our company since February 2016. Currently Dr. Quinn is President and Chief Executive Officer of Aeglea BioTherapeutics, Inc., a biotechnology company where he has served on the Board of Directors since April 2015 as CEO since July 2018 and as interim CEO from July 2017 to July 2018. Prior to that, from October 2015 to July 2017 he worked as a private consultant for IDBioPharm Consulting LLC, a consulting firm. From August 2009 to June 2015 Dr. Quinn served as Head of Research & Development and Chief Medical Officer for Synageva BioPharma Corp., a publicly traded biopharmaceutical company that was acquired by Alexion Pharmaceuticals, Inc. in June 2015. Following the acquisition, Dr. Quinn worked for Alexion Pharmaceuticals, Inc., a pharmaceutical company, from June 2015 to September 2015. Dr. Quinn received his BMSc. in general pathology and his MB ChB M.D. from the University of Dundee, U.K. and his Ph.D. in cancer research from the University of Newcastle in Tyne, U.K. He completed a postdoctoral fellowship at University of California, San Francisco before being appointed Professor of Dermatology at Barts & The London School of Medicine, U.K. He is a fellow of the Royal College of Physicians London. He has also served as a member of the board of directors for Generation Bio since December 2017.
高管简历
中英对照 | 中文 | 英文- Daniel L. Menichella
Daniel L.Menichella自2020年10月起担任我们的首席执行官兼总裁兼董事。在成为首席执行官之前，他于2017年1月担任CureVac Inc.’；S美国子公司的首席执行官，然后于2018年6月接任该国际公司的首席执行官。在此之前，Menichella先生曾担任多家公司的首席商务官，包括Bamboo Therapeutics Inc.（2015年至2016年），2013年至2015年担任Applied Genetic Technologies Corporation AGTC，以及Zyngenia，Inc.（2011年至2013年）。Menichella先生还从2007年到2011年领导Talecris Biopharmicals的业务开发和公司战略职能部门，从2002年到2007年领导Merck KGaA的业务开发和公司战略部门。他在哈佛大学获得文学士学位，在北卡罗来纳大学教堂山分校获得工商管理硕士学位。
Daniel L. Menichella has served as our Chief Executive Officer and President and as a Director since October 2020. Prior to becoming Chief Executive Officer, he served as the chief executive officer for CureVac Inc.’s U.S. subsidiary in January 2017 before taking over as CEO of the international company in June 2018. Prior to that, Mr. Menichella was Chief Business Officer at several companies, including Bamboo Therapeutics Inc. from 2015-2016 Applied Genetic Technologies Corporation AGTC from 2013-2015 and Zyngenia, Inc. from 2011-2013. Mr. Menichella also led Business Development and Corporate Strategy functions at Talecris Biopharmaceuticals from 2007-2011 and at Merck KGaA from 2002-2007. He earned his Bachelor of Arts from Harvard University and his Master of Business Administration from the University of North Carolina at Chapel Hill.- Daniel L.Menichella自2020年10月起担任我们的首席执行官兼总裁兼董事。在成为首席执行官之前，他于2017年1月担任CureVac Inc.’；S美国子公司的首席执行官，然后于2018年6月接任该国际公司的首席执行官。在此之前，Menichella先生曾担任多家公司的首席商务官，包括Bamboo Therapeutics Inc.（2015年至2016年），2013年至2015年担任Applied Genetic Technologies Corporation AGTC，以及Zyngenia，Inc.（2011年至2013年）。Menichella先生还从2007年到2011年领导Talecris Biopharmicals的业务开发和公司战略职能部门，从2002年到2007年领导Merck KGaA的业务开发和公司战略部门。他在哈佛大学获得文学士学位，在北卡罗来纳大学教堂山分校获得工商管理硕士学位。
- Daniel L. Menichella has served as our Chief Executive Officer and President and as a Director since October 2020. Prior to becoming Chief Executive Officer, he served as the chief executive officer for CureVac Inc.’s U.S. subsidiary in January 2017 before taking over as CEO of the international company in June 2018. Prior to that, Mr. Menichella was Chief Business Officer at several companies, including Bamboo Therapeutics Inc. from 2015-2016 Applied Genetic Technologies Corporation AGTC from 2013-2015 and Zyngenia, Inc. from 2011-2013. Mr. Menichella also led Business Development and Corporate Strategy functions at Talecris Biopharmaceuticals from 2007-2011 and at Merck KGaA from 2002-2007. He earned his Bachelor of Arts from Harvard University and his Master of Business Administration from the University of North Carolina at Chapel Hill.
- William Duke, Jr.
William Duke，Jr.自2019年11月起担任我们的首席财务官。在加入我们之前，杜克先生于2015年6月至2019年11月担任Pulmatrix，Inc.的首席财务官。加入Pulmatrix之前，他曾担任Valeritas, Inc.公司（医疗技术公司）的首席财务官（从2014年1月到2015年6月），以及Valeritas公司的副总裁兼公司财务总监（从2011年7月到2014年1月）。在Valeritas，Duke先生领导了财务总监关系、财务规划和分析、投资者关系和信息技术职能部门。加入Valeritas公司之前，他曾担任健赞公司公司（生物制药公司）的高级财务董事（从2010年1月到2011年7月），在那里他曾负责监督证券交易委员会的外部报告、内部管理报告和全球财务整合。任职Genzyme公司之前，他曾担任Haemonetics Corporation公司（医疗设备公司）的财务和会计董事（从2008年5月到2010年1月），也曾担任多种高级财务职务，涉及咨询服务和新兴增长组织。Duke先生拥有Stonehill College会计学士学位和Bentley University财务硕士学位，是一名注册会计师。
William Duke, Jr. has served as our Chief Financial Officer since November 2019. Prior to joining us, Mr. Duke served as the chief financial officer for Pulmatrix, Inc from June 2015 to November 2019. Prior to Pulmatrix, Mr. Duke served as the Chief Financial Officer of Valeritas, Inc. a medical technology company, from January 2014 until June 2015 and from July 2011 until January 2014 he served as Valeritas’ Vice President and Corporate Controller. At Valeritas, Mr. Duke led the controller relationship, financial planning and analysis, investor relations and information technology functions. Prior to joining Valeritas, Mr. Duke was Senior Director, Finance for Genzyme Corporation, a biopharmaceutical company, from January 2010 to July 2011 where he had oversight responsibility for external reporting to the Securities and Exchange Commission, internal management reporting and worldwide financial consolidation. Prior to Genzyme, he was the Director of Finance and Accounting of Haemonetics Corporation, a medical device company, from May 2008 to January 2010 and held various senior financial roles with consulting services and emerging growth organizations. Mr. Duke holds a B.S. in Accounting from Stonehill College and a M.B.A. with a concentration in Finance from Bentley University and is a Certified Public Accountant.- William Duke，Jr.自2019年11月起担任我们的首席财务官。在加入我们之前，杜克先生于2015年6月至2019年11月担任Pulmatrix，Inc.的首席财务官。加入Pulmatrix之前，他曾担任Valeritas, Inc.公司（医疗技术公司）的首席财务官（从2014年1月到2015年6月），以及Valeritas公司的副总裁兼公司财务总监（从2011年7月到2014年1月）。在Valeritas，Duke先生领导了财务总监关系、财务规划和分析、投资者关系和信息技术职能部门。加入Valeritas公司之前，他曾担任健赞公司公司（生物制药公司）的高级财务董事（从2010年1月到2011年7月），在那里他曾负责监督证券交易委员会的外部报告、内部管理报告和全球财务整合。任职Genzyme公司之前，他曾担任Haemonetics Corporation公司（医疗设备公司）的财务和会计董事（从2008年5月到2010年1月），也曾担任多种高级财务职务，涉及咨询服务和新兴增长组织。Duke先生拥有Stonehill College会计学士学位和Bentley University财务硕士学位，是一名注册会计师。
- William Duke, Jr. has served as our Chief Financial Officer since November 2019. Prior to joining us, Mr. Duke served as the chief financial officer for Pulmatrix, Inc from June 2015 to November 2019. Prior to Pulmatrix, Mr. Duke served as the Chief Financial Officer of Valeritas, Inc. a medical technology company, from January 2014 until June 2015 and from July 2011 until January 2014 he served as Valeritas’ Vice President and Corporate Controller. At Valeritas, Mr. Duke led the controller relationship, financial planning and analysis, investor relations and information technology functions. Prior to joining Valeritas, Mr. Duke was Senior Director, Finance for Genzyme Corporation, a biopharmaceutical company, from January 2010 to July 2011 where he had oversight responsibility for external reporting to the Securities and Exchange Commission, internal management reporting and worldwide financial consolidation. Prior to Genzyme, he was the Director of Finance and Accounting of Haemonetics Corporation, a medical device company, from May 2008 to January 2010 and held various senior financial roles with consulting services and emerging growth organizations. Mr. Duke holds a B.S. in Accounting from Stonehill College and a M.B.A. with a concentration in Finance from Bentley University and is a Certified Public Accountant.
- Johan van Hylckama Vlieg
Johan vanHylckama Vlieg自2019年7月起担任我们的首席科学官。Van Hylckama Vlieg博士在肠道微生物学，益生菌和活体生物疗法以及工业和学术界的工业生物技术领域拥有25年的领导团队和研发计划的经验。最近，他担任CHR的微生物和人类健康创新副总裁。Hansen在丹麦，负责益生菌和治疗应用的新菌株开发，从发现到临床开发和新技术平台。此前，Van Hylckama Vlieg博士在Danone Research工作，并在Nizo Food Research担任多个职位。他在荷兰格罗宁根大学完成了生物化学博士和博士后。
Johan van Hylckama Vlieg has served as our Chief Scientific Officer since July 2019. Dr. van Hylckama Vlieg has 25 years of experience leading teams and R&D programs in gut microbiology, probiotics and live biotherapeutics, and industrial biotechnology in industry and academia. Most recently, he served as Vice President for Microbiome and Human Health Innovation at Chr. Hansen in Denmark, responsible for new strain development for probiotic and therapeutic application, spanning discovery to clinical development and novel technology platforms. Previously, Dr. van Hylckama Vlieg worked at Danone Research and in several roles at NIZO Food Research. He completed his Ph.D. and post-doc in biochemistry at the University of Groningen in the Netherlands.- Johan vanHylckama Vlieg自2019年7月起担任我们的首席科学官。Van Hylckama Vlieg博士在肠道微生物学，益生菌和活体生物疗法以及工业和学术界的工业生物技术领域拥有25年的领导团队和研发计划的经验。最近，他担任CHR的微生物和人类健康创新副总裁。Hansen在丹麦，负责益生菌和治疗应用的新菌株开发，从发现到临床开发和新技术平台。此前，Van Hylckama Vlieg博士在Danone Research工作，并在Nizo Food Research担任多个职位。他在荷兰格罗宁根大学完成了生物化学博士和博士后。
- Johan van Hylckama Vlieg has served as our Chief Scientific Officer since July 2019. Dr. van Hylckama Vlieg has 25 years of experience leading teams and R&D programs in gut microbiology, probiotics and live biotherapeutics, and industrial biotechnology in industry and academia. Most recently, he served as Vice President for Microbiome and Human Health Innovation at Chr. Hansen in Denmark, responsible for new strain development for probiotic and therapeutic application, spanning discovery to clinical development and novel technology platforms. Previously, Dr. van Hylckama Vlieg worked at Danone Research and in several roles at NIZO Food Research. He completed his Ph.D. and post-doc in biochemistry at the University of Groningen in the Netherlands.
- Jerald Korn
Jerald Korn自2019年7月起担任我们的总法律顾问兼公司秘书，自2021年1月起担任总法律顾问，公司秘书兼首席行政官。在加入我们之前，Korn先生于2015年4月至2019年7月在Tesaro, Inc.担任过各种职务，包括总法律顾问兼首席行政官，全球首席合规官和副总法律顾问，助理总法律顾问兼合规官。在加入Tesaro之前，Korn先生于2013年8月至2015年3月担任Cubist Pharmaceuticals, Inc.的副总法律顾问，2011年7月至2013年8月担任Millennium Pharmaceuticals的副首席合规官，并担任AMAG Pharmaceuticals的副总法律顾问兼合规官，从2008年8月到2011年7月担任公司董事。在加入AMAG Pharmaceuticals之前，他是Ropes&Gray LLP律师事务所的合伙人。Korn先生拥有哈佛大学的学士学位和波士顿大学法学院的法学博士学位。
Jerald Korn has served as our General Counsel and Corporate Secretary since July 2019 and as General Counsel, Corporate Secretary and Chief Administrative Officer since January 2021. Prior to joining us, Mr. Korn served in various roles at TESARO, Inc. from April 2015 to July 2019 including General Counsel and Chief Administrative Officer, Global Chief Compliance Officer and Deputy General Counsel, and Assistant General Counsel and Compliance Officer. Prior to TESARO, Mr. Korn served as Associate General Counsel at Cubist Pharmaceuticals, Inc. from August 2013 to March 2015 as Deputy Chief Compliance Officer at Millennium Pharmaceuticals from July 2011 to August 2013 and as Associate General Counsel and Compliance Officer at AMAG Pharmaceuticals, Inc. from August 2008 to July 2011. Prior to AMAG Pharmaceuticals, he was an associate in the law firm of Ropes & Gray LLP. Mr. Korn holds a bachelor’s degree from Harvard University and J.D. from Boston University School of Law.- Jerald Korn自2019年7月起担任我们的总法律顾问兼公司秘书，自2021年1月起担任总法律顾问，公司秘书兼首席行政官。在加入我们之前，Korn先生于2015年4月至2019年7月在Tesaro, Inc.担任过各种职务，包括总法律顾问兼首席行政官，全球首席合规官和副总法律顾问，助理总法律顾问兼合规官。在加入Tesaro之前，Korn先生于2013年8月至2015年3月担任Cubist Pharmaceuticals, Inc.的副总法律顾问，2011年7月至2013年8月担任Millennium Pharmaceuticals的副首席合规官，并担任AMAG Pharmaceuticals的副总法律顾问兼合规官，从2008年8月到2011年7月担任公司董事。在加入AMAG Pharmaceuticals之前，他是Ropes&Gray LLP律师事务所的合伙人。Korn先生拥有哈佛大学的学士学位和波士顿大学法学院的法学博士学位。
- Jerald Korn has served as our General Counsel and Corporate Secretary since July 2019 and as General Counsel, Corporate Secretary and Chief Administrative Officer since January 2021. Prior to joining us, Mr. Korn served in various roles at TESARO, Inc. from April 2015 to July 2019 including General Counsel and Chief Administrative Officer, Global Chief Compliance Officer and Deputy General Counsel, and Assistant General Counsel and Compliance Officer. Prior to TESARO, Mr. Korn served as Associate General Counsel at Cubist Pharmaceuticals, Inc. from August 2013 to March 2015 as Deputy Chief Compliance Officer at Millennium Pharmaceuticals from July 2011 to August 2013 and as Associate General Counsel and Compliance Officer at AMAG Pharmaceuticals, Inc. from August 2008 to July 2011. Prior to AMAG Pharmaceuticals, he was an associate in the law firm of Ropes & Gray LLP. Mr. Korn holds a bachelor’s degree from Harvard University and J.D. from Boston University School of Law.